Vancouver, Canada – February 19, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, is pleased to announce its participation in the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting, taking place February 26 – March 1 in Calgary, Alberta. We invite attendees to visit Booth #18 to explore our latest advancements in rheumatology diagnostics.
This annual meeting brings together leading Canadian and international rheumatologists, researchers, and healthcare professionals to discuss the latest developments in rheumatic disease diagnostics, treatment strategies, and precision medicine.
Early and accurate diagnosis remains a critical challenge in rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). Many patients experience years of diagnostic delay and disease management challenges, leading to disease progression and reduced treatment effectiveness.
At CRA 2025, we will highlight how biomarker-driven solutions, including JOINTstat (14-3-3eta biomarker) for RA and SPINEstat (Anti-14-3-3eta Multiplex biomarker) for axSpA, can support earlier detection and more informed clinical decision-making.
We look forward to engaging in discussions on the future of rheumatology diagnostics and disease management. If you are attending CRA 2025, be sure to visit us at booth #18 to connect and learn more about our innovative solutions.
Learn more about the event here:
CRA 2025 Annual Scientific Meeting
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3eta protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]